You are here

glioblastoma

The Fastest Growing Cancer Company You've Never Heard Of

The Fastest Growing Cancer Company You've Never Heard Of

Motley Fool

tumor treating fields

pancreatic cancer

Flag link:

Bristol-Myers’ checkpoint star Opdivo fails a PhIII study for glioblastoma

Bristol-Myers’ checkpoint star Opdivo fails a PhIII study for glioblastoma

Endpoints

Bristol-Myers Squibb

clinical trials

Flag link:

FDA Allows Ziopharm Brain Cancer Drug Trial

FDA Allows Ziopharm Brain Cancer Drug Trial

Investopedia

clinical trials

Flag link:

CAR-T therapy makes early inroads in treating brain cancer

CAR-T therapy makes early inroads in treating brain cancer

Stat

Flag link:

Celgene CEO: myeloma and glioblastoma both priorities

Celgene CEO: myeloma and glioblastoma both priorities

BioPharma Dive

Multiple Myeloma

Flag link:

3 Shocking Biotech Flops of 2016 So Far

3 Shocking Biotech Flops of 2016 So Far

Motley Fool

Celldex Therapeutics

Clovis Oncology

NewLink Genetics

algenpantucel-L

pancreatic cancer

Flag link:

AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting

AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting

Yahoo

Flag link:

CTRC doctor wins $1.6 million FDA orphan grant to treat deadly brain tumors

CTRC doctor wins $1.6 million FDA orphan grant to treat deadly brain tumors

phys.org

Threshold Pharmaceuticals

Flag link:

Northwest Bio Fuzzier on Cancer Vaccine Study Patient Enrollment

Northwest Bio Fuzzier on Cancer Vaccine Study Patient Enrollment

TheStreet.com

Northwest Biotherapeutics

Flag link:

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data in Patients with Newly Diagnosed Glioblastoma at the 2014 ASCO Annual Meeting

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data in Patients with Newly Diagnosed Glioblastoma at the 2014 ASCO Annual Meeting

Yahoo/PR NewsWire

ImmunoCellular Therapeutics

Flag link:

Roche May Share Trial Data on Avastin Amid Brain Cancer Conflict

Roche May Share Trial Data on Avastin Amid Brain Cancer Conflict

Bloomberg

Flag link:

Agenus: How Meaningful Is The Prophage Phase II Data?

Agenus: How Meaningful Is The Prophage Phase II Data?

Seeking Alpha

Flag link:

Celldex, ImmunoCellular Fall And Rise On Hype And Hope

Celldex, ImmunoCellular Fall And Rise On Hype And Hope

Seeking Alpha

ImmunoCellular Therapeutics

Flag link:

Celldex: A View On The Imminent Release Of Data For The Cancer Vaccine Rindopepimut

Celldex: A View On The Imminent Release Of Data For The Cancer Vaccine Rindopepimut

Seeking Alpha

Flag link:

A Promising Platform for Cancer Immunotherapy

A Promising Platform for Cancer Immunotherapy

Motley Fool

Flag link:

Roche's Avastin fails to prolong survival in brain cancer study

Roche's Avastin fails to prolong survival in brain cancer study

Reuters

Flag link:

Celldex Releases Data, Biostar Announces Q3 Results Date: Healthcare Business Review

Celldex Releases Data, Biostar Announces Q3 Results Date: Healthcare Business Review

Wall Street Cheat Street

Biostar Pharmaceuticals

Flag link:

Threshold announces preliminary data from TH-302 study

Threshold announces preliminary data from TH-302 study

Yahoo/Fly on the Wall

Threshold Pharmaceuticals

Flag link:

Threshold Pharmaceuticals Announces Preliminary Data From Phase 1/2 Study of TH-302 in Combination With Bevacizumab in Patients With Recurrent Glioblastoma

Threshold Pharmaceuticals Announces Preliminary Data From Phase 1/2 Study of TH-302 in Combination With Bevacizumab in Patients With Recurrent Glioblastoma

Yahoo/MarketWire

Threshold Pharmaceuticals

Flag link:

Roche says Avastin slows brain cancer tumor growth

Roche says Avastin slows brain cancer tumor growth

Reuters

Flag link: